Objectives. The aim was to explore the function of the T-cell cytokine IFNg for mesenchymal tissue remodelling in RA and to determine whether IFNg signalling controls the invasive potential of fibroblastlike synoviocytes (FLS).
Introduction
RA is a systemic inflammatory disease that primarily affects the synovium of diarthrodial joints. As a hallmark, fibroblast-like synoviocytes (FLS) reorganize to form an aggressive cell mass that extends into and destroys the articular cartilage and bone. The aberrant behaviour of RA FLS may be driven by the cytokine milieu that is produced by infiltrating immune cells [1] , including T cells [2] . Cooperation between T cells and FLS may contribute to persistent destructive synovitis. So far, however, few studies have explored the effects of T cells on FLS functions; FLS that were co-cultured with T cells demonstrated increased expression of co-stimulatory molecules [3] and released increased amounts of tissue-degrading enzymes [4] as well as pro-inflammatory chemokines/ cytokines when compared with FLS cultured without T cells [5] . Direct cell-to-cell interactions between FLS and T cells, as well as T-cell-derived cytokines might be responsible for these effects. Indeed, the Th-1 cytokine IFNg [6] , which is expressed in rheumatoid synovitis [2] , was shown to modulate collagen and metalloproteinase synthesis in FLS [7, 8] . These studies indicate that IFNg affects FLS functions. Its significance for inflammatory synovial tissue remodelling and FLS invasive potential, however, remains elusive. In this study, we explore the capacity of IFNg and its downstream signalling machinery to induce synovial tissue remodelling and to modulate the invasive behaviour of FLS.
Methods

Isolation and culture of FLS
With approval of the Ethics Committee of the Medical University of Vienna and according to the Declaration of Helsinki, FLS from 27 patients fulfilling the ACR/EULAR classification criteria for RA [9] were isolated and cultured as previously described [10] . Demographic and clinical characteristics of the patients are shown in supplementary  Table S1 , available at Rheumatology Online.
Primary antibodies, fluorescent dyes, cytokines and inhibitors Primary antibodies for western blot were as follows: from Cell Signaling, Danvers, MA, USA: focal adhesion kinase (FAK; clone D2R2E, dilution 1:1000), p-FAK (Y576/577; 1:1000), p-FAK (Y397; D20B1; 1:1000), p-FAK (Y925; 1:1000), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkBa) (44D4; 1:1000), Janus kinase (JAK1; 6G4; 1:1000), JAK2 (D2E12; 1:1000), Signal transducer and activator of transcription 1 (STAT1) (9H2; 1:1000) and p-STAT1 (58D6; 1:1000); and from Sigma-Aldrich, St. Louis, MO, USA: actin (1:1000). Primary antibodies were used as suggested by the manufacturer. Dyes for immunofluorescence staining were as follows: CellTracker Green CMFDA (Thermo Fisher, Waltham, MA, USA; 1:400), CellTracker Deep Red (Thermo Fisher; 1:500) and CellTracker Red CMTPX (Thermo Fisher; 1:400). Dyes were used as suggested by the manufacturer. Cytokines, from R&D Systems, Minneapolis, MN, USA, were as follows: IFNa, IFNb, IFNg and TNF. The concentration used for interferons was 100 U/ml, and for TNF 10 ng/ml. The inhibitor, baricitinib, was purchased from Selleckchem, Houston, TX, USA.
Small interfering RNA experiments
The FLS were transfected with 50 nM of small interfering RNA (siRNA) pools (JAK1: ON-TARGETplus SMARTpool L-003145-00-0005; JAK2: ON-TARGETplus SMARTpool L-003146-00-0005; ThermoScientific, Waltham, MA, USA) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) [11] .
Synovial micromass cultures
Micromass organ cultures were constructed as described by Kiener et al. [10] . After variable times of culture (728 days), the spheres were fixed with paraformaldehyde and embedded in paraffin. Paraffin-embedded sections were stained with Haematoxylin and Eosin. Pictures were taken with an Axioskop 2 microscope (Zeiss Oberkochen, BadenWurttemberg, Germany) equipped with a digital camera (Olympus, Shinjuku, Tokyo, Japan).
For confocal live cell imaging, FLS were dyed with CellTracker Green (CMFDA), Red (CMTMR) and Deep Red. Imaging was done with a Leica TSC SP5 microscope (Leica, Wetzlar, Hesse, Germany). Images were processed with Imaris Bitplane software (Bitplane, Belfast, United Kingdom).
Cell migration assay
Polycarbonate membranes (24-well insert, pore size 8 mm; Sigma Aldrich, St. Louis, Missouri, USA) were coated with fibronectin ( Fig. 1C ; Life Technologies, Carlsbad, Carlifornia, USA) or fetal bovine serum (supplementary Fig. S1 , available at Rheumatology Online; Hyclone by GE Healtcare (Little Chalfont, United Kingdom)). FLS were plated in the top chamber. FLS that migrated to the underside of the membrane were fixed with methanol, stained with Vectashield (Vector Laboratories, Burlingame, California, USA) and counted using a fluorescence microscope (Zeiss).
Western blot FLS were lysed in radioimmunoprecipitation assay buffer supplemented with phosphatase and protease inhibitors (Roche, Basel, Switzerland). Proteins were separated by electrophoresis, followed by electrotransfer onto nitrocellulose membranes. After blocking, membranes were incubated with primary and horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology, Danvers, MA, USA). Specific bands were detected with the ECL detection kit (Pierce, Waltham, Massachusetts, USA). Reblots were performed using ReBlot Plus Strong Stripping Solution (Millipore, Burlington, Massachusetts, USA). ImageJ (US National Institutes of Health, Bethesda, MD, USA) was used to quantify gel bands.
Invasion assay
The previously described matrix-associated transepithelial resistance invasion assay was used to assess FLS invasive capacity [12] .
Statistical analysis
For parametrically distributed data, Student's paired t-tests were used for comparing paired samples. If data were not normally distributed, Wilcoxon matched pairs non-parametric tests were applied instead. Student's paired t-tests and Wilcoxon matched pairs non-parametric tests were performed using GraphPad Prism software (GraphPad, San Diego, CA, USA). To evaluate the invasive capacity of FLS over time depending on the type of stimulation (IFNg, baricitinib, IFNg + baricitinib; Fig. 2E ), the generalized estimated equation analyses incorporated in the SPSS package 24 (IBM) were used.
Results
In RA, FLS reorganize and give rise to pathological pannus tissue that destroys the articular cartilage and bone. To explore whether IFNg drives tissue remodelling in arthritis, we used a three-dimensional in vitro model (Fig. 1A and B) that was shown faithfully to recapitulate many in vivo functions of the synovial membrane [10] . Consistent with previous data, lining formation with compacted cells at the tissue interface was observed for control micromasses (Fig. 1A) . In contrast, IFNg stimulation resulted in attenuated lining formation, with less tightly packed cells oriented in parallel to the surface of the sphere (Fig. 1A and supplementary Fig. S2A , available at Rheumatology Online). Similar to the control, the sublining FLS were scattered, with wide extracellular space between individual cells, but demonstrated a more elongated cellular phenotype, with long cellular extensions (Fig. 1B) . In contrast, TNF induced pronounced aggregation of FLS in both the lining and the sublining area ( Fig. 1A  and B; supplementary Fig. S2 , available at Rheumatology Online) [10] . This indicates that IFNg affects synovial tissue remodelling in a different manner from TNF.
Cellular organization in tissues depends upon tight control of cellular motility. Recognizing distinct structural effects of IFNg in synovial micromass cultures, we probed whether IFNg regulates FLS motility. Indeed, migration assays revealed an increased migratory activity for IFNg-stimulated compared with unstimulated FLS (Fig. 1C; supplementary Fig. S1 , available at Rheumatology Online).
Given that FAK controls cell migration by regulating focal adhesion turnover [13] , we next determined FAK phosphorylation upon cytokine stimulation. Although phosphorylation of Y397 and Y576/Y577 was not affected, IFNg increased FAK-Y925 phosphorylation ( Fig. 2A; supplementary Fig. S3A , available at Rheumatology Online). IFNa/IFNb and TNF stimulation resulted in the expected activation of the JAK-STAT1 or the nuclear factor-kB pathway, as shown by the phosphorylation of STAT1 or the degradation of IkBa, respectively, but neither type I IFNs (IFNa and IFNb) nor TNF increased the phosphorylation of FAK ( Fig. 2B; supplementary Fig.  S3B , available at Rheumatology Online), indicating that Y925 phosphorylation of FAK is a distinct characteristic of IFNg, but not of type I IFNs or TNF.
IFNg mediates its effects via JAKs [6] . To address whether JAK1, JAK2 or both are involved in FAK activation, we silenced JAK expression with specific siRNA pools. Intriguingly, knockdown of JAK2, but not JAK1, consistently abrogated the IFNg-induced phosphorylation of FAK-Y925 ( Fig. 2C; supplementary Fig. S3C , available at Rheumatology Online). In line with these observations, baricitinib, a JAK1/JAK2 inhibitor that has recently been approved for the treatment of RA patients [14] , decreased IFNg-induced FAK-Y925 phosphorylation in a dose-dependent manner ( Fig. 2D; supplementary Fig. S3D , available at Rheumatology Online).
Based on our observations, we reasoned that baricitinib might limit the invasive potential of IFNg-stimulated FLS. Using a recently described invasion assay [12] , we observed an increased invasive capacity for IFNg-stimulated FLS when compared with unstimulated FLS (control vs IFNg, P < 0.0001; Fig. 2E ). Moreover, inhibition of JAKs by baricitinib abrogated the IFNg-induced invasive behaviour (IFNg vs IFNg + baricitinib, P = 0.005; Fig. 2E ).
Discussion
Research into the mechanisms defining FLS activity in RA suggests that soluble mediators, such as cytokines secreted by leucocytes, play a key role. Notably, TNFa and IL1b are known to enhance FLS aggressiveness as well as pro-inflammatory cytokine and matrix metalloproteinase production [1] . Herein, we report on a T-cell cytokine, namely IFNg, that has hitherto not been directly linked to FLS migration and invasion. Using an in vitro model of the synovium [10] , we observed IFNg-induced synovial architectural changes that were strikingly different from that induced by TNF. These changes were accompanied by an increased migratory and invasive FLS phenotype and pronounced FAK activity. FAK is a tyrosine kinase that promotes normal as well as tumour cell migration and invasion. Recent evidence indicates that FAK is a determining factor for the aggressive behaviour of RA FLS. When compared with healthy synovial tissues, increased FAK activity was detected in rheumatoid synovitis [15] . Moreover, epigenetic studies identified the FAK pathway as a hotspot for epigenetic alterations in RA FLS [16] .
The mechanisms that induce FAK activation include integrin-mediated FAK autophosphorylation at Y397 and Proto-oncogene tyrosine-protein kinase Src-mediated phosphorylation of the FAK kinase domain activation loop (Y576/Y577) [13] . Confirming a previous observation [17] , we found constitutively activated Y397 and Y576/Y577 in cultured RA FLS. The phosphorylation of both Y397 and Y576/Y577 was not affected by IFNg or the other cytokines tested. Importantly, IFNg stimulation distinctly promoted FAK phosphorylation at the less well-characterized phosphosite, Y925. The importance of Y925 for FAK-mediated cell migration and invasion was recently demonstrated by non-phosphorylatable and phosphomimetic mutants. FAK knockout mouse embryonic fibroblasts that expressed the non-phosphorylatable Y925F-FAK showed decreased focal adhesion turnover and reduced cell migration [18] .
In line with a reported association between JAK2 and FAK after growth hormone stimulation [19] , our silencing experiments reveal that FAK activation by IFNg is mediated by JAK2. This suggests that emerging RA therapeutics that target JAK2 would inhibit the herein reported IFNg-JAK2-FAK signalling cascade and may, thus, prevent IFNg-induced cartilage invasion by FLS. Indeed, we demonstrate that baricitinib inhibits the IFNg-induced invasive capacity of FLS. As IFNg is expressed in rheumatoid synovitis [2] , this pathway might contribute to destructive events beyond those mediated by the injurious cytokines TNF and IL-6.
In conclusion, here we contribute evidence that IFNg promotes the migratory and invasive behaviour of FLS via the activation of JAK2 and FAK. This study provides a molecular basis for the structural efficacy of novel targeted RA therapeutics, such as baricitinib, and suggests that JAK inhibitors not only target immune cells but also the stromal compartment of RA.
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